Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557294 · ClinicalTrials.gov registry record · Phase 4
Varenicline OTC Trial on Efficacy and Safety
A Phase 4 study of Smoking Cessation and Tobacco Dependence, sponsored by Arizona State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 313
- Enrollment target
- 2
- Study locations
NCT03557294 is a Phase 4 study of Smoking Cessation and Tobacco Dependence that has completed, run by Arizona State University. The registered enrollment target is 313 participants, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (34% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03557294, a Phase 4 study of Smoking Cessation and Tobacco Dependence, has completed, sponsored by Arizona State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 313 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
Conditions Studied
Interventions
- DRUG 1.0mg Varenicline b.i.d.
- DRUG 0.5mg Varenicline b.i.d.
- DRUG 0.0mg placebo Varenicline b.i.d.
Study Locations (2)
Arizona
- Arizona State University - Phoenix
California
- Los Angeles Clinical Trials - Burbank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2022-04-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557294
The ClinicalTrials.gov registry entry for NCT03557294 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 188 other Smoking Cessation trials with a reported enrollment target (34% lower). The listed sponsor is Arizona State University, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which 1.0mg Varenicline b.i.d. is the first listed.
NCT03557294 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03557294 about?
NCT03557294 is a clinical study titled "Varenicline OTC Trial on Efficacy and Safety". The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
What is the current status of trial NCT03557294?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 313 participants. The study started on 2018-05-07. Estimated completion is 2022-04-16.
What conditions does trial NCT03557294 study?
This clinical trial studies the following conditions: Smoking Cessation, Tobacco Dependence, Withdrawal Symptoms.
What interventions are being tested in trial NCT03557294?
The interventions under investigation include: 1.0mg Varenicline b.i.d. (DRUG), 0.5mg Varenicline b.i.d. (DRUG), 0.0mg placebo Varenicline b.i.d. (DRUG).
Who is sponsoring clinical trial NCT03557294?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03557294 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.